drugset
drugset / Trial / NCT05348356

Nirogacestat in Ovarian Granulosa Cell Tumors

NCT05348356 ↗

Phase 2 Completed 53 enrolled SpringWorks Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This phase 2 clinical trial will study the effectiveness of nirogacestat in ovarian granulosa cell tumors (OvGCTs). Nirogacestat is a gamma secretase inhibitor (GSI) which is hypothesized to decrease the growth and activity of ovarian granulosa tumors.

Timeline

Start
2022-08-30
Primary completion
2025-07-08
Completion
2025-07-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Nirogacestat Small molecule 150 mg Oral

Indications

ovarian cancer ovarian granulosa cell tumor